SA
Create Free Alerts
Alto Neuroscience, Inc.ANRONYSE
Loading
OverviewIntelligenceChartsNews

Latest News

Alto Neuroscience Announces $120 Million Private Placement Financing
businesswire.com

Alto Neuroscience Announces $120 Million Private Placement Financing

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing.

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
businesswire.com

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “Alto enters 2026 with a very strong clinical and financial foundation,” said Amit Etkin, M.D., Ph.D., founder and.

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
businesswire.com

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investo.

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
businesswire.com

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50.

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
businesswire.com

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the.

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
businesswire.com

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience's leadership team, Patricio O'Donn.

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
businesswire.com

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec.

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
businesswire.com

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #ACNP--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company's development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026. “We are pleased to have the opportunity to showcas.

Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why
defenseworld.net

Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why

Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) were down 6% during mid-day trading on Friday. The company traded as low as $16.90 and last traded at $16.74. Approximately 59,931 shares changed hands during trading, a decline of 86% from the average daily volume of 425,848 shares. The stock had previously closed

Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.
defenseworld.net

Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.

AWM Investment Company Inc. trimmed its stake in shares of Alto Neuroscience, Inc. (NYSE: ANRO) by 68.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,483 shares of the company's stock after selling 621,501 shares during the

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
businesswire.com

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto's Board of Directors granted a new employee an option to purchase 150,000 shares of Alto's common stock. The stock option was granted under Alto's 2025 Inducement Plan as a mate.

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026
seekingalpha.com

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Alto Neuroscience, Inc. is positioned as a precision medicine innovator in CNS disorders, with major clinical readouts expected in 2026. ANRO's pipeline targets high unmet needs in depression, bipolar disorder, and schizophrenia, leveraging biomarkers to optimize drug efficacy and patient selection. The company has a strong cash runway into 2028, experienced leadership, and potential for significant upside if upcoming trials are successful.

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
businesswire.com

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “These past months marked a period of significant strategic execution and validation for Alto. The successful outcome.

Alto Neuroscience to Participate in Upcoming Investor Conferences
businesswire.com

Alto Neuroscience to Participate in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 1.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance